Prostatic Hyperplasia: Clinical Trials

54 trials for Prostatic Hyperplasia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

54 completed. 54 Phase 2, 8 Phase 3, 6 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 254Completed 54
Phase 38Completed 8
Phase 16Completed 6

Follow Prostatic Hyperplasia: new trials by email Literature Review of Prostatic Hyperplasia trials Research Report on Prostatic Hyperplasia

Trials (filtered) newest first · largest first

All 54 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
RADA16 for Aquablation Day Case
PuraStat - Hematuria, Benign Prostatic Hyperplasia
Phase 2CompletedNYU Langone Health242026-05-142026-11-09
The Additive Value of Pyridostigmine to Silodosin in Acute Urinary Retention
silodosin 8 mg capsule and the pyridostigmine bromide 60 mg tablet, silodosin 8 mg capsule - Prostatic Hyperplasia
Phase 2CompletedBeni-Suef University1402023-02-012024-03-20
The Effectiveness of Spermotrend Food Supplement in the Treatment of Male Infertility
Spermotrend - Male Infertility, Benign Prostatic Hyperplasia
Phase 2 / Phase 3CompletedCatalysis SL1502021-06-152023-03-28
Teverelix Evaluated in Advanced Prostate Cancer
teverelix TFA 120 mg, teverelix TFA 180 mg - Prostatic Adenoma
Phase 2CompletedAntev Ltd.502021-03-042024-07-23
Composite Steep-pulseTreatment Device Used in Patients With Benign Prostatic Hyperplasia
Composite Steep-pulse Treatment Device, Tamsulosin Hydrochloride Capsules - Benign Prostatic Hyperplasia
Phase 2 / Phase 3CompletedREMD Medical Technology1602020-08-202022-09-07
The Effect of Traditional Chinese Medicine on Benign Prostatic Hyperplasia
VGH-BPH1, Placebo (Corn starch pill manufactured to mimic VGH-BPH1) - Benign Prostatic Hyperplasia
Phase 1 / Phase 2CompletedTaipei Veterans General Hospital, Taiwan232019-03-062020-04-13
Optilumeā„¢ BPH Prostatic Drug Coated Balloon Dilation Catheter
Optilumeā„¢ BPH Prostatic DCB Dilation Catheter, Paclitaxel - Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy
Phase 2CompletedUrotronic Inc.802017-12-192025-11-26
Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)
Fedovapagon 2 mg, Placebo - Nocturia
Phase 2 / Phase 3CompletedVantia Ltd4322016-03-012018-10-31
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH
Placebo, GV1001 - Benign Prostatic Hyperplasia (BPH)
Phase 2CompletedGemVax & Kael1612015-10-012022-03-04
A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
talaporfin sodium, Saline, Drug Activator 100 J/cm - Benign Prostatic Hyperplasia
Phase 2CompletedLight Sciences Oncology2252014-11-012018-08-08
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
WC3055, Placebo - Benign Prostatic Hyperplasia
Phase 2CompletedWarner Chilcott7962013-08-012015-06-29
Prostate Embolization for Benign Prostatic Hyperplasia
Prostatic Embolization with Embosphere Micropsheres - Benign Prostatic Hyperplasia
Phase 1 / Phase 2CompletedJames B. Spies, MD152013-08-012019-12-10
A Study to Evaluate the Efficacy and Safety of ASP4901 in Patients With Benign Prostate Hyperplasia
ASP4901, Tamsulosin, Placebo - Benign Prostate Hyperplasia
Phase 2CompletedAstellas Pharma Inc3202013-07-222024-11-06
Prostatic Artery Embolization for Benign Prostatic Hyperplasia
Prostate artery embolization - Benign Prostate Hyperplasia
Phase 2 / Phase 3CompletedSaskatchewan Health Authority - Regina Area132013-03-012016-04-07
Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels
Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD), Doxazosin 4 mg every day (QD) - Benign Prostatic Hyperplasia
Phase 2CompletedBuddhist Tzu Chi General Hospital1402012-08-012014-07-15
Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With BPH and LUTS
onaBoNT-A + placebo, Tamsulosin + placebo - Benign Prostatic Hyperplasia, Lower Urinary Track Symptoms
Phase 2CompletedVA Office of Research and Development632012-06-012021-10-05
Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy
Degarelix - Prostate Cancer
Phase 2CompletedBritish Columbia Cancer Agency502012-04-012020-01-27
Evaluation of Finastride Effect in Different Dosage on the Amount of Perioperative Bleeding in Transurthral Resection of Prostate
TURP - Benign Prostate Hyperplasia
Phase 2 / Phase 3CompletedShiraz University of Medical Sciences602012-01-012016-04-20
Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)
PRX302, Placebo - Benign Prostatic Hyperplasia
Phase 1 / Phase 2CompletedSophiris Bio Corp402011-09-012013-08-21
An Efficacy Trial of Electroacupuncture at Points of Bilateral BL33 for Mild and Moderate Benign Prostatic Hyperplasia
needle - Benign Prostatic Hyperplasia (BPH)
Phase 2CompletedGuang'anmen Hospital of China Academy of Chinese Medical Sciences1002010-09-012013-05-27

Showing 20 of 54. Sign in to see all of them.

Narrower conditions

Lower Urinary Tract Symptoms (7)  ·  Nocturia (2)  ·  Prostatic Neoplasms (2)  ·  Eunuchism (1)  ·  Genital Diseases (1)  ·  Hematuria (1)  ·  Infertility, Male (1)  ·  Lymphoma, Follicular (1)  ·  Muscular Atrophy (1)  ·  Prostatic Diseases (1)  ·  Prostatism (1)  ·  Prostatitis (1)  ·  Sarcopenia (1)

Broader conditions

Genital Diseases, Male (54)  ·  Male Urogenital Diseases (54)  ·  Urogenital Diseases (54)  ·  Genital Diseases (53)  ·  Prostatic Diseases (53)  ·  Pathological Conditions, Signs and Symptoms (11)  ·  Signs and Symptoms (11)  ·  Urological Manifestations (10)  ·  Lower Urinary Tract Symptoms (3)  ·  Neoplasms (3)  ·  Genital Neoplasms, Male (2)  ·  Neoplasms by Site (2)  ·  Urogenital Neoplasms (2)  ·  Atrophy (1)  ·  Endocrine System Diseases (1)

Interventions

Tamsulosin (7)  ·  Botulinum Toxins, Type A (6)  ·  Tadalafil (5)  ·  Saline Solution (3)  ·  silodosin (3)  ·  1-(6-ethoxy-5-(3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo(4,3-d)pyrimidin-5-yl)-3-pyridyl sulphonyl)-4-ethylpiperazine (2)  ·  Finasteride (2)  ·  PRX302 (2)  ·  Sodium Chloride (2)  ·  Talaporfin (2)  ·  Transurethral Resection of Prostate (2)  ·  Vardenafil Dihydrochloride (2)  ·  acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (2)  ·  Acupuncture Therapy (1)  ·  Celecoxib (1)

Sponsors

Eli Lilly and Company (5)  ·  Allergan (3)  ·  Astellas Pharma Inc (2)  ·  Bayer (2)  ·  Light Sciences Oncology (2)  ·  Pfizer (2)  ·  Sophiris Bio Corp (2)  ·  VA Office of Research and Development (2)  ·  American Medical Systems (1)  ·  Antev Ltd. (1)  ·  Ausio Pharmaceuticals, LLC (1)  ·  Beni-Suef University (1)  ·  Boehringer Ingelheim (1)  ·  British Columbia Cancer Agency (1)  ·  Buddhist Tzu Chi General Hospital (1)

Countries

United States (22)  ·  Canada (8)  ·  Germany (6)  ·  South Korea (5)  ·  Czechia (4)  ·  Japan (4)  ·  Slovakia (4)  ·  Australia (3)  ·  France (3)  ·  Italy (3)  ·  Poland (3)  ·  Taiwan (3)  ·  United Kingdom (3)  ·  Austria (2)  ·  China (2)

Top investigators

Albertas Ulys, MD (1)  ·  Allan J Pantuck, MD, MS, FACS (1)  ·  Christopher Kelly, MD (1)  ·  Christopher P Smith, MD (1)  ·  Donald Bergner, MD (1)  ·  Hann-Chorng Kuo, M.D. (1)  ·  Herman Ellman, MD (1)

Results publications

PMID 21791356, PMID 12893330, PMID 15126771, PMID 18461049, PMID 18722631, PMID 19409693, PMID 20163842, PMID 21943105, PMID 23098762, PMID 23537687, PMID 23593139, PMID 24012740, PMID 24326421, PMID 25873370, PMID 26299520, PMID 26945662, PMID 27842331, PMID 28053292, PMID 29228755, PMID 29398594, PMID 37354260, PMID 38311868

NIH funding

U01DK060817 (1)